Maintenance therapy with interferon-α after high-dose treatment with stem cell support in multiple myeloma has been intensively debated. In this study, we evaluated the response to treatment with interferon-α in relation to genetic variation in genes related to inflammation.
Introduction
Interferon-alpha (INF-α) as maintenance therapy after high-dose therapy (HDT) for multiple myeloma (MM) has been intensively debated during the last 30 years because several clinical studies have been published with conflicting results. Barlogie et al. randomized responders after HDT to INF-α or observation, and found no benefit of IFN-α treatment. 1 In another randomized trial of maintenance treatment with IFN-α following high-dose chemotherapy in MM, progression-free survival and overall survival (OS) were significantly prolonged in the treated group in comparison to the control group. 2 These results were later confirmed by the Myeloma Trialists' Collaborative Group in a meta-analysis of 1543 patients treated with IFN-α as maintenance treatment. They found an increase in progression-free survival of 6 months and a small, but significant, improvement in OS. 3 IFN-α is an antiviral and immunomodulating drug which, in a complex manner, interferes with both the innate and adaptive immune systems. 4 Furthermore, IFN-α induces apoptosis or growth arrest in myeloma cells. Survival of myeloma cells is dependent on interactions with bone marrow stromal cells. In the bone marrow, the myeloma cells stimulate both the production of the pro-inflammatory cytokines interleukin-1beta (IL-1β) and interleukin-6 (IL-6) and angiogenesis and thereby potentiate their own growth in autocrine and paracrine fashions. In this process, nuclear factor-κB (NF-κB) is a key regulator of the inflammatory response and NF-κB has been shown to link inflammation with cancer. 5 Genes activated by the NF-κB pathway include many pro-inflammatory cytokines, such as IL1B and IL6. It is, therefore, possible that the outcome of IFN-α maintenance treatment is related to inborn variation in genes involved in inflammation. Previously, we have shown that the polymorphism IL1B T-31C is associated with the both risk of MM and survival after HDT. 6 Furthermore, we have shown that genetic variation in the DNA repair genes ERCC2 (excision-repair cross-complementing 2), XRCC3 (X-ray repair cross-complementing group 3) and CD3EAP (CD3e molecule, epsilon associated protein) influence treatment outcome in MM patients undergoing HDT. 7 In the present study, we addressed the question of whether inborn variation in genes involved in inflammation influence outcome of IFN-α maintenance treatment of patients with MM after HDT. We selected polymorphisms known to be functionally important. The C allele of the promoter polymorphism IL1B T-31C results in increased IL-1β secretion upon stimulation with lipopolysaccharide. 8, 9 The polymorphism IL6 G-174C is also located in the promoter region of the gene. The wild type G allele is found to have a higher transcriptional level than the variant C-allele and the presence of the Callele in healthy individuals results in low IL-6 levels and low lymphocyte levels upon stimulation. 10 The NFKB1 -94ins/delATTG promoter polymorphism has been suspected to be involved in susceptibility to ulcerative colitis, but the relevance of this polymorphism in MM is unknown. 11 The polymorphism is an insertion/deletion of four bases in the promoter region of the NFKB1 gene encoding both of the NF-κB transcription factors, p50 and p105. The allele containing the deletion is less able to bind transcription factors and produces lower transcript levels in luciferase reporter systems. Consequently, carriers of the del-allele have lower levels of NF-κB. 11 The gene CD3EAP, also named CAST and ASE-1 (anti-sense to excision-repair cross-completing 1, ERCC1) is of interest, since this gene may be involved in the regulation of T-cell function. 12 The variant A-allele has been associated with increased risks of basal cell carcinoma, breast cancer and lung cancer. [13] [14] [15] PPP1R13L (protein phosphate 1, regulatory (inhibitory) subunit 13 like, also named RAI or iASPP) encodes an inhibitor of the RelA subunit of NF-κB. 16 It is, therefore, possible that polymorphisms affecting the activity of PPP1R13L could influence the activity of NK-κB.
In this study we tested whether the polymorphisms IL1B T-31C, IL6 G-174C, NFKB1 -94ins/delATTG, CD3EAP G-21A and PPP1R13L IVS1 A4364G influence the efficacy of IFN-α maintenance treatment after HDT in patients with MM. In order to do this, we retrospectively studied a population of 296 patients with MM who underwent HDT in Denmark between 1994 and 2004.
Design and Methods

Subjects, clinical data, response criteria, eligibility criteria, and treatment
Subjects, clinical data, response criteria, and eligibility criteria have previously been described in detail. 7 Briefly, patients diagnosed with MM and treated with high-dose melphalan and stem cell support from August 1994 to August 2004 were recruited from four participating centers in Denmark. Three hundred forty-eight patients were included in the study. Of these, 185 patients were included in the high-dose treatment protocols organized by the Nordic Myeloma Study Group (NMSG no. 5/94, 7/98 and 11/00), [17] [18] [19] whereas the remaining 163 patients were treated with similar treatment regimens, but not registered in these protocols. The patients' were staged according to Durie and Salmon and the International Staging System (ISS). Time-to-treatment failure (TTF) and OS were calculated from date of stem cell infusion to date of progression or death. Progression was defined by a more than 25% increase in serum M-protein or 25% increase in immunoglobulin levels above upper normal levels, confirmed by two separate measurements within a 1-month interval. An increase in bone marrow infiltration of plasma cells by 25%, an increase of Bence-Jones proteinuria to more than 1.0 g/24 h or other signs of progression such as hypercalcemia, progressive skeletal disease or soft-tissue plasmacytoma were also considered as progression. Eleven patients died during HDT. Two patients died from malignancies other than MM, and two patients died due to other non-MM causes. The occurrence of other malignancies and death without progression was regarded as events not related to progression. These patients were included in the analysis of OS, but they were excluded at time of death from the analy-sis of TTF. The median follow-up after HDT was 54.5 months, (range, 0.4 to 163 months). The median survival after HDT was 70.1 months.
Induction therapy consisted of three courses of VAD (vincristine, doxorubicin and dexamethasone) or two or three courses of cyclophosphamide 1 g/m 2 i.v. on day 1 combined with dexamethasone 40 mg daily p.o., on days 1-4 and days 9-11 (total dose 320 mg for each course) repeated every 3 weeks. Peripheral blood stem cells were harvested at regeneration after cyclophosphamide priming, and the patients thereafter underwent HDT with melphalan (200 mg/m 2 ) followed by stem cell support. Fifty-three patients received a second HDT up-front. Data on maintenance therapy were collected retrospectively from the medical records. Maintenance therapy with IFN-α was implemented 3 months after HDT according to standard treatment pratice in the particular region (median 105 days). The percentage of patients treated with IFN-α varied from 12% in one region to 71% in another. More than 3 months of treatment with IFN-α was required for inclusion in the treatment group. Twenty patients were treated with IFN-α for less than 3 months and were included in the control group. Medical information on IFN-α was unknown for six patients, and these patients were excluded from the study. Forty-six patients suffered from recurrence of disease within 6 month after HDT and were, therefore, excluded from the study. The median duration of IFN-α treatment was 425 days (range, 162-914). The planned IFN-α therapy was a dose of 5×10 6 U s.c. 3 times a week, but the dose was adjusted to levels tolerated by the patient. Two hundred and ninety-six patients were included in the study and of these, 146 patients were treated with IFN-α. The study was approved by the Danish Ethical Committee (01-158/03).
Human tissue samples
Peripheral blood mononuclear cells were purified from 292 leukapheresis products by buffy coat preparation. From 56 patients ten 10 µm sections were collected from paraffin-embedded bone marrow samples. Material was not available for 19 patients undergoing HDT and these patients were not included in the study.
DNA purification
DNA for analysis was purified from peripheral blood mononuclear cells by the salting out method 20 or from paraffin-embedded tissue by phenol extraction as described elsewhere.
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Genotyping of single nucleotide polymorphisms
Genotypes were determined on an ABI 7500 analyzer using endpoint readings. Reactions were performed on 5 µL containing approximately 50 ng DNA, 2.5 µL mastermix (Applied Biosystems, Birkerød, Denmark), 100 nM of each probe and 900 nM primers. Controls were included in each run, and a repeat analysis of a 10% subset of samples yielded 100% identical genotypes. Moreover, for ten persons, DNA from both bone marrow and leukapheresis products was typed with identical results.
IL1B T-31C (rs1143627), IL6 G-174C (rs1800795) CD3EAP G-21A (rs967591), and PPP1R13L IVS1 A4364G (rs1970764) were genotyped as previously described. 
Statistical methods
SPSS
Results
Study population
Two hundred and ninety-six patients were included in the study from a population of 348 patients with MM who underwent HDT in Denmark between 1994 and 2004 as described earlier. 7 The demographic and clinical data of the patients included in this study are presented in Table 1 and Figure 1 . There were no statistically significant differences between the group treated with IFN-α and the group not treated with IFN-α in relation to levels of β2-microglobulin, creatinine, albumin and sex. However, patients treated with IFN-α were younger than controls and had higher Durie-Salmon stages of disease. There was no difference in the ISS criteria. 
Single nucleotide polymorphisms
Genotypes of IL1B T-31C, IL6 G-174C, NFKB1 -94ins/delATTG, CD3EAP G-21A and PPP1R13L IVS1 A4364G were determined. There were no differences in genotype distributions among patients from different participating centers. Table 2 shows the genotype distributions of IL1B T-31C, IL6 G-174C, NFKB1 -94ins/delATTG, CD3EAP G-21A and PPP1R13L IVS1 A4364G among patients who did or did not receive IFN-α maintenance treatment. TTF and OS were compared in groups subdivided by genotypes and IFN-α treatment (Table 2 and Figure 2A , B, C and D). We compared genotypes within treatment arms with homozygous carriers of the wild type allele serving as the reference and we compared carriers of the same genotype in the presence and absence of IFN-α treatment, untreated patients serving as the reference. To test whether the effect of INF-α treatment was dependent on genotype, we performed a Cox proportional hazard analysis including an interaction term between INF-α treatment and the genotypes. If this term has a p value of less than 0.05, the effect of INF-α treatment is significantly different between genotypes (Table 3 , only p values for interaction term shown corrected for other prognostic markers are shown).
The ins-allele of NFKB1 -94ins/delATTG was associated with an effect on TTF and OS (Table 2 ). In a multivariate Cox analysis, testing whether INF-α treatment had different effects depending on genotype, the effect of the ins-allele was related to treatment with IFN-α (p=0.01 and p=0.04) (Figure 2A and B and Table 3 ). Among Figure 2C ) when analyzed by multivariate Cox analysis (Table 3 ) and among patients treated with IFN-α, there was no difference in TTF or OS in relation to the genotype distribution of IL6 G-174C. However, among patients who did not receive treatment with IFN-α, carriers of the wild type G allele IL6 G-174C had a longer OS and median survival was not reached at a follow-up of 120 months after HDT, whereas carriers of the variant C allele had a median survival of 64.6 months (p=0.007) ( Figure 2D ). In a multivariate Cox analysis, the GG-genotype of IL6 G-174C remained significant for untreated patients when adjusted for age, sex and β2-microglobulin (Table 3 ; p=0.01).
The genotype distribution of NFKB1 -94ins/delATTG was as follows: 91 ins-carriers (wild type), 143 heterozygous carriers and 46 homozygous del-carriers, and for IL6 G-174C the genotype distribution was: 72 GG-carriers (wild type), 149 CG-carriers and 68 CC-carriers. We tested the distribution of baseline characteristics between treatment groups for NFKB1 -94ins/delATTG and IL6 G-174C and found no differences (Table 4) . Furthermore, no difference was found in response status after HDT in relation to allele distribution and treatment status of IFN-α (Table 5 ). There was no difference in duration of IFN-α treatment and in time to progression after cessation of IFN-α between patients with the IL6 G-174C and NFKB1 -94ins/delATTG genotypes. By univariate analysis, age and sex were found to be prognostic markers for TTF, and β2-microglobulin, age and sex were found to be prognostic markers for OS in this population of patients. There was no difference in results when data were adjusted for these prognostic factors. In multivariate analysis of IFN-α treated patients, age (p=0.02), sex (p=0.04), and the wild type ins/ins-genotype of NFKB1 -94ins/delATTG (p=0.0001), remained prognostic markers for TTF, and for OS the wild type ins-allele of NFKB1 -94ins/delATTG (p=0.02) was found to be a prognostic marker together with age (p= 0.02), sex (p=0.04) and β2-microglobulin (p=0.001). In untreated patients the wild type GG-genotype of IL6 G-174C remained a prognostic marker (p=0.04) for OS together with β2-microglobulin (p=0.02).
Patients treated with IFN-α and carrying the variant allele C allele IL1B T-31C had a prolonged TTF (29.6 months and 48.0 months) and OS (70.9 months and infinity) as compared to homozygous carriers of the T allele, but when tested in a multivariate Cox analysis, the analysis showed that the difference in TTF and OS was not related to treatment with IFN-α (Table 3 ; p=0.09 and p=0. 21) . In relation to the polymorphism CD3EAP G-21A, carriers of the variant G allele had significant longer TTF and OS as compared to those with the wild type Aallele. When data were correlated to effect of treatment with IFN-α in multivariate Cox analysis, there was no association. The polymorphism PPP1R13L IVS1 A4364G was not associated with differences in TTF and OS and no difference between treatment groups was seen when the data were analyzed by multivariate Cox analysis. 
Discussion
We have previously shown that inborn variations in genes involved in DNA-repair are important for TTF in MM patients treated with HDT. 7 In this study, we addressed the question of whether inborn variations in genes related to inflammation are important for the effect of IFN-α maintenance treatment after HDT. Formerly, many myeloma patients received maintenance treatment with IFN-α after HDT. Today, maintenance treatment with IFN-α is not considered the standard of care after HDT due to the uncertainty of the results from previously published clinical studies and because of side effects of the treatment. In this study, treatment with IFN-α was initiated 3 months after HDT and patients treated for less than 3 months with IFN-α were excluded from the treatment group and placed in the untreated group since no effect of IFN-α would be expected. However, re-analysis of the data excluding these patients from the untreated group did not change the results (results not shown). As a consequence of this design, patients with the poorest prognosis and with recurrence of disease within 6 months after HDT were not included in the study. Due to the uncontrolled retrospective design of our study, the IFN-α treatment group included younger patients (54 versus 57 years, p=0.005) with more advanced Durie -Salmon stage (p=0.02) than the group of untreated patients. This could potentially have resulted in a selection bias since less healthy patients may not be offered IFN, but the different treatment strategy between regions makes it less likely. However, this potential selection bias should not influence the association between genotype and treatment outcome within the two IFN treatment groups.
We, therefore, analyzed whether inborn variations in genes involved in the inflammatory response influenced TTF and OS in subgroups of myeloma patients treated with IFN-α. When compared within the IFN-α treatment group, patients carrying the wild type allele of NFKB1 -94ins/delATTG did not have a significantly prolonged TTF, although this was increased from 34.4 months to 49.9 months, probably because of the low number of patients. However, the result was significant in a multivariate Cox analysis. TTF was significantly increased when the comparison was performed in relation to genotype and Figure 1A shows a clear separation of wild type ins-carriers from ins-carriers among patients not treated with IFN-α and del-carriers treated or not with IFN-α.
No difference in treatment duration of IFN-α was found in relation to genotype distribution of NFKB1 -94ins/delATTG, which indicates that the difference in TTF is not a result of early cessation of IFN-α treatment caused by side effects. Figure 1A also illustrates that patients not treated with IFN-α carrying the wild type ins-allele had a shorter TTF than patients not treated with IFN-α carrying the variant del-allele. These findings are not statistically significant, but may indicate that NF-κB is not the only player in the activation pathway of IFN-α.
Patients carrying the wild type ins-allele of NFKB1 -94ins/delATTG had significantly longer OS when treated with IFN-α compared to treated variant allele carriers and also compared to all untreated patients regardless of genotype status.
In humans, both IFN and NF-κB are central players in the regulation of apoptosis and cell growth and in the modulation of the immune system. A normal function of NF-κB is essential for the innate and adaptive immune systems and it is, therefore, interesting that IFN-α treated myeloma patients with a normal level of NF-κB had a significantly prolonged OS. 4 This may indicate that the effect of IFN-α treatment is dependent on the availability of NF-κB. This hypothesis is supported by a recent finding that the effect of IFN-γ was mediated through a JAK-STAT-NKκB signaling pathway in corticotroph tumor cells producing adrenocorticotrophin hormone. 23 Patients who were not treated with IFN-α and carried the wild type G allele of IL6 G-174C had a longer OS compared to patients carrying the C allele of IL6 G-174C. The polymorphism was not associated with TTF and it is not, therefore, possible to exclude that the difference in OS was caused by later treatment modalities. IFN-α induces IL-6 and IL-6 is important for normal development of B cells and plasma cells and is known to induce proliferation of pluripotent stem cells. Our study indicates that a normal, high transcription level of the IL6 gene gives patients with MM a survival advantage.
Patients diagnosed with MM cannot be cured in spite of intensive treatment strategies with single or tandem HDT. It is, therefore, important to establish maintenance treatment strategies that are well-tolerated and result in a good quality of life for the patients. Patients treated with IFN-α may experience side effects such as emotional and social impairment, fatigue, pain and loss of appetite. The side effects disappear when treatment is withdrawn. In a recent randomized cross-over study quality of life was considerably better in patients treated with pegylated IFN α2b than in patients treated with IFN-α. 24 New maintenance treatments for MM patients, including thalidomide, prednisone, bortezomib and lenalidomide have been proposed and studied. These treatment modalities are associated with potentially worse side effects than treatment with IFN-α. Peripheral neuropathy is a common side effect of treatment with both thalidomide and bortezomib, and may be severe and irreversible and affect daily life activities. We report that the NFKB1 -94ins/delATTG polymorphism may select patients with MM who could benefit particularly from maintenance treatment with IFN-α after HDT. We suggest that maintenance treatment with IFN-α (maybe pegylated IFN α2b) should still be considered after HDT for patients carrying the wild type ins/ins genotype of NFKB1 -94ins/delATTG. A prospective study of IFN-α treatment in relation to NFKB1 -94ins/delATTG is warranted.
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